Pirtobrutinib — Global Competitive Landscape Report 2026 | EHA 2026

Pirtobrutinib is a major EHA 2026 CLL keyword through LB5001, the BRUIN CLL-322 Phase 3 trial testing fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab. It is useful for articles on non-covalent BTK inhibitors, post-covalent BTK inhibitor sequencing, and fixed-duration CLL therapy.

This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes.

Executive Summary

Pirtobrutinib (Jaypirca, LOXO-305) is the first FDA-approved non-covalent (reversible) Bruton tyrosine kinase inhibitor. Redx Pharma originated the molecule and Loxo Oncology / Eli Lilly took it through development. The FDA granted accelerated approval on 2023-01-27 for relapsed or refractory mantle cell lymphoma after at least two prior lines including a covalent BTKi. A second FDA accelerated approval followed for adults with CLL or SLL after a BTKi and a BCL2 inhibitor. EMA’s CHMP issued a positive opinion on 2025-02-28 for relapsed or refractory CLL after a covalent BTKi.

Notably, the Patsnap Eureka pharma-intelligence stack returns 389 BTK-targeting drug records, 752 BTK-related patents filed since January 2023, 864 active CLL Phase 2 or Phase 3 trials, and 70 trials with pirtobrutinib as the main investigational drug. Within that pool, three approved covalent BTKis (ibrutinib, acalabrutinib, zanubrutinib) anchor the legacy class while a wave of BTK degraders (NX-5948, NX-2127, BGB-16673, Bexobrutideg, Catadegbrutinib) opens the next architecture.

As a result, EHA 2026 LB5001 (BRUIN CLL-322) is the year’s defining pirtobrutinib readout. The trial tests whether adding a non-covalent BTKi to the venetoclax-rituximab backbone deepens fixed-duration response in previously treated CLL or SLL, without a confused or overlapping covalent-BTKi mechanism. The strategic question goes beyond C481S resistance: it asks whether non-covalent BTKi can carve out a fixed-duration role that covalent agents have struggled to claim.

---

Traditionally, compiling this level of analysis would require weeks of manual research across platforms like Google Patents and PubMed. With Eureka LS, the same process can be automated — from extracting molecules to mapping competitive pipelines — into a structured output like the report below.

Arena Overview

Pirtobrutinib MoA snapshot — Pirtobrutinib is a small-molecule, non-covalent, reversible BTK inhibitor with low-nanomolar potency against both wild-type BTK and the C481S-mutant kinase. Crucially, it does not bind C481. Instead, it forms hydrogen bonds with non-cysteine residues and water molecules near the ATP-binding site. This binding mode also blocks Y551 phosphorylation in the BTK activation loop. As a result, pirtobrutinib retains activity in patients whose disease has progressed on ibrutinib, acalabrutinib, or zanubrutinib through a C481S substitution.

BTK-targeting field (389 records) — Among BTK-targeting drug records, the field divides into three architectures: covalent BTKis (ibrutinib, acalabrutinib, zanubrutinib, orelabrutinib, tirabrutinib, rocbrutinib, remibrutinib, rilzabrutinib, tolebrutinib), non-covalent BTKis (pirtobrutinib, nemtabrutinib, fenebrutinib, vecabrutinib), and BTK degraders (Bexobrutideg, Catadegbrutinib, NX-5948, NX-2127, BGB-16673). Recent Asian launches (rocbrutinib 2026-06-03; remibrutinib 2025-09-30; rilzabrutinib 2025-07-08) extend the covalent class into autoimmune and oncology indications.

BTK patent activity (since 2023) — In addition, assignees have filed 752 BTK-related patent families since January 2023. The filings span next-generation non-covalent scaffolds, BTK PROTACs targeting both wild-type and resistance variants (T474, L528W, A428D), BTK + IKZF1/IKZF3 dual degraders (zelebrudomide, NX-2127), and combination protocols pairing BTK inhibition with BCL2 inhibitors and anti-CD20 antibodies.

Player Summary Table

Player	Region	Tier	Primary Route	Key Evidence
Eli Lilly / Loxo Oncology	US	T1 (Leader)	Non-covalent BTKi (Jaypirca)	Pirtobrutinib (2023-01-27 MCL; 2023-12 CLL/SLL); BRUIN, BRUIN MCL-321, BRUIN CLL-322 (EHA 2026 LB5001), BRUIN CLL-321
AbbVie / Janssen (Imbruvica)	US	T1 (Incumbent)	1st-gen covalent BTKi	Ibrutinib (2013); RESONATE-2; class-defining ibrutinib + venetoclax + obinutuzumab combinations
AstraZeneca	UK	T1 (Challenger)	2nd-gen covalent BTKi	Acalabrutinib (Calquence, 2017); ELEVATE-RR vs ibrutinib; preferred CLL frontline in many guidelines
BeiGene / BeOne Medicines	CN/US	T1 (Challenger)	2nd-gen covalent BTKi	Zanubrutinib (Brukinsa, 2019); ALPINE PFS win vs ibrutinib; SEQUOIA frontline data
Merck (MSD)	US	T2 (Non-covalent challenger)	Non-covalent BTKi	Nemtabrutinib (MK-1026, ARQ-531) — Phase 2; CLL ORR ~58%; pre-medication-friendly profile
Roche / Genentech	US/CH	T2 (Reversible BTKi)	Reversible non-covalent BTKi	Fenebrutinib (GDC-0853) — pivoted from B-cell oncology to MS / autoimmune disease
InnoCare Pharma	CN	T2 (Covalent + degrader)	Covalent BTKi + ICP-490 CELMoD	Orelabrutinib (2020); ICP-490 BTK + IKZF1/IKZF3 program
Ono Pharmaceutical	JP	T2 (Regional covalent)	Covalent BTKi	Tirabrutinib (Velexbru, 2020); Japan-led PCNSL data
Nurix Therapeutics	US	T2 (Degrader)	BTK degrader	Bexobrutideg / NX-5948 — Phase 1 in CLL/NHL; rapid sustained BTK degradation
BeiGene (BGB-16673)	CN/US	T2 (Degrader)	BTK degrader	BGB-16673 — Phase 1 in B-cell malignancies; activity at lowest dose level
Catalyst Pharmaceuticals (Catadegbrutinib)	US	T3 (Degrader)	BTK PROTAC	Catadegbrutinib — preclinical; structurally distinct PROTAC scaffold
Hutchmed	CN/UK	T3 (Non-covalent)	Non-covalent BTKi	HMPL-760 — Phase 1 in B-cell malignancies; oral non-covalent design
Sanofi (Rilzabrutinib)	FR	T2 (Autoimmune)	Reversible covalent BTKi	Rilzabrutinib (2025-07-08); ITP and immunology indications, not CLL
Novartis (Remibrutinib)	CH	T2 (Autoimmune)	Covalent BTKi	Remibrutinib (2025-09-30); chronic spontaneous urticaria; non-oncology positioning
Sanofi (Tolebrutinib)	FR	T2 (CNS)	CNS-penetrant covalent BTKi	Tolebrutinib (2025-08-27); progressive multiple sclerosis

---

Route Differentiation Analysis

In particular, three architectural routes define how pirtobrutinib competes in CLL and beyond. Each strength level draws from MCP pipeline records and the published trial evidence.

Route × Player Matrix

Player	Covalent BTKi	Non-covalent BTKi	BTK Degrader	BCL2-paired Combination	Anti-CD20-paired Combination
Eli Lilly / Loxo	Absent	Strong — Pirtobrutinib (Jaypirca)	Absent	Strong — BRUIN CLL-322 with venetoclax	Strong — BRUIN CLL-322 with rituximab
AbbVie / Janssen	Strong — Ibrutinib (Imbruvica)	Absent	Absent	Strong — IbrV-O frontline	Moderate — IbrR
AstraZeneca	Strong — Acalabrutinib (Calquence)	Absent	Absent	Moderate — AVO frontline	Moderate — A-Obi
BeiGene / BeOne	Strong — Zanubrutinib + BGB-16673 degrader	Absent	Moderate — BGB-16673	Emerging — sonrotoclax + zanubrutinib	Moderate
Merck	Absent	Moderate — Nemtabrutinib (MK-1026)	Absent	Absent	Absent
Roche / Genentech	Absent	Moderate — Fenebrutinib (autoimmune pivot)	Absent	Absent	Absent — moved to MS
InnoCare	Moderate — Orelabrutinib	Absent	Emerging — ICP-490 IKZF/CRBN	Absent	Absent
Ono Pharmaceutical	Moderate — Tirabrutinib (Velexbru)	Absent	Absent	Absent	Absent
Nurix	Absent	Absent	Strong — NX-5948 (Bexobrutideg) + NX-2127 dual	Absent	Absent
Catalyst (Catadegbrutinib)	Absent	Absent	Emerging — preclinical PROTAC	Absent	Absent
Hutchmed	Absent	Emerging — HMPL-760	Absent	Absent	Absent

Route Concentration Observations

• Covalent BTKi — Additionally, ibrutinib, acalabrutinib, and zanubrutinib still own the frontline CLL slot. Long-term studies show only 1.7-3% of frontline patients develop BTK or PLCG2 mutations, so first-line covalent BTKi is durable. Resistance becomes the dominant story only at second relapse.
• Non-covalent BTKi — Meanwhile, pirtobrutinib leads alone after FDA approval in 2023. Nemtabrutinib (Merck) follows in Phase 2 with 58% ORR in CLL. Fenebrutinib (Roche) pivoted to multiple sclerosis after the Genentech Phase 1 ended early.
• BTK degrader — In contrast, the PROTAC class targets both wild-type BTK and resistance variants (C481S, T474, L528W, A428D). Nurix’s NX-5948 and NX-2127, BeiGene’s BGB-16673, and Catalyst’s Catadegbrutinib all sit in Phase 1 with encouraging early activity in patients who have already cycled through both covalent and non-covalent BTKis.
• BCL2-paired combinations — Similarly, venetoclax pairs with every BTKi class. Pirtobrutinib + venetoclax + rituximab (BRUIN CLL-322, EHA 2026 LB5001) tests whether a non-covalent BTKi turns this triplet into a fixed-duration regimen.
• Anti-CD20-paired combinations — Furthermore, BRUIN CLL-322 deliberately pairs pirtobrutinib with rituximab rather than obinutuzumab. The xlsx note specifically flags this distinction: confusing the comparator with obinutuzumab is a common content-pipeline error.

---

Top Player Deep Dives

1. Eli Lilly / Loxo Oncology (Tier 1 — Non-covalent BTKi leader)

Primary route: First-in-class non-covalent (reversible) BTK inhibitor.

Key product: Pirtobrutinib (Jaypirca, LOXO-305) — FDA accelerated approval 2023-01-27 for relapsed or refractory mantle cell lymphoma; CLL/SLL approval followed in late 2023; EMA CHMP positive opinion 2025-02-28 for relapsed or refractory CLL.

Pivotal trials: BRUIN Phase 1/2 (NCT03740529) demonstrated ORR 57.8% in MCL after covalent BTKi exposure and ORR 62-82% in CLL/SLL. BRUIN CLL-321 evaluates pirtobrutinib monotherapy versus IdelaR or BR. BRUIN CLL-322 (EHA 2026 LB5001) is the fixed-duration Phase 3 of pirtobrutinib + venetoclax + rituximab versus venetoclax + rituximab in previously treated CLL or SLL.

Differentiation: Notably, pirtobrutinib retains activity in C481S-mutant disease and across kinase-impaired BTK variants. As a result, it serves as the salvage agent of choice after covalent BTKi failure.

Trajectory: Moreover, BRUIN CLL-322 tries to expand the use case from salvage to fixed-duration combination therapy. A positive readout would establish the first non-covalent BTKi role in time-limited CLL regimens.

Key risk: However, BTK degraders (NX-5948, BGB-16673) are catching up fast. Real-world resistance to pirtobrutinib already shows kinase-impaired variants (T474, L528W) emerging in 55% of progressors in BRUIN. The non-covalent advantage compresses as PROTACs degrade both wild-type and mutant BTK simultaneously.

BTKi Class Generational Comparison

Generation	Mechanism	Lead Agent	FDA Approval	C481S Activity
1st-gen covalent	Irreversible C481 binder	Ibrutinib	2013-11-13	Lost (resistance)
2nd-gen covalent	More selective C481 binder	Acalabrutinib (2017), Zanubrutinib (2019)	2017-10-31 / 2019-11-14	Lost (same C481 dependency)
1st non-covalent	Reversible, ATP-pocket adjacent	Pirtobrutinib	2023-01-27	Retained
Other non-covalent	Reversible	Nemtabrutinib (MK-1026), Fenebrutinib	Phase 2	Retained
BTK degrader	PROTAC, recruits E3 ligase	NX-5948 (Bexobrutideg), BGB-16673, NX-2127	Phase 1	Retained for all variants

2. AbbVie / Janssen — Ibrutinib (Tier 1 — Covalent incumbent)

Primary route: First-in-class irreversible covalent BTK inhibitor.

Key product: Ibrutinib (Imbruvica) — FDA approved 2013-11-13. RESONATE-2 established frontline CLL benefit. Long-term follow-up shows progression-free survival benefit out to 8+ years in untreated disease.

Differentiation: Specifically, ibrutinib defined the BTKi category and remains the comparator in most head-to-head trials. AbbVie shares CLL revenue with Janssen.

Trajectory: In addition, ibrutinib has lost ELEVATE-RR (vs acalabrutinib) and ALPINE (vs zanubrutinib) on PFS or safety endpoints. Frontline share is migrating to the second-generation agents.

Key risk: However, atrial fibrillation, hypertension, and bleeding signal limit ibrutinib’s outpatient ergonomics. BTK degraders threaten its post-relapse role.

3. AstraZeneca — Acalabrutinib (Tier 1 — 2nd-gen covalent)

Primary route: Second-generation selective covalent BTK inhibitor.

Key product: Acalabrutinib (Calquence) — FDA approved 2017-10-31. ELEVATE-RR demonstrated non-inferior PFS and significantly lower atrial fibrillation versus ibrutinib in relapsed or refractory CLL.

Differentiation: In particular, acalabrutinib reduces off-target EGFR and TEC kinase inhibition. As a result, cardiovascular and bleeding tolerability improves.

Trajectory: Furthermore, AVO (acalabrutinib + venetoclax + obinutuzumab) and AcaR combinations cover frontline and relapsed settings. Acalabrutinib is already a guideline-preferred frontline option.

Key risk: However, ELEVATE-RR resistance data show that 66% of progressors developed BTK mutations (mostly C481S). Pirtobrutinib and BTK degraders sit downstream waiting.

4. BeiGene / BeOne Medicines — Zanubrutinib (Tier 1 — 2nd-gen covalent)

Primary route: Second-generation selective covalent BTK inhibitor.

Key product: Zanubrutinib (Brukinsa) — FDA approved 2019-11-14. ALPINE Phase 3 demonstrated PFS superiority over ibrutinib in relapsed or refractory CLL — the first head-to-head BTKi PFS win.

Differentiation: Specifically, zanubrutinib offers twice-daily dosing and improved BTK occupancy. SEQUOIA establishes frontline activity.

Trajectory: Moreover, BeiGene/BeOne also runs BGB-16673 (BTK PROTAC degrader) and pairs zanubrutinib with sonrotoclax, its proprietary BCL2 inhibitor. The vertical-integration strategy hedges across all three BTK architectures.

Key risk: However, BeiGene rebranded to BeOne Medicines amid US-China regulatory tension. Operating between geographies remains structurally exposed.

5. Merck — Nemtabrutinib (Tier 2 — Non-covalent challenger)

Primary route: Non-covalent reversible BTK inhibitor.

Key product: Nemtabrutinib (MK-1026, formerly ARQ-531) — Phase 2 in B-cell malignancies. Phase 2 ORR ~58% in CLL with covalent BTKi and BCL2i exposure.

Differentiation: Notably, nemtabrutinib offers an alternative non-covalent scaffold to pirtobrutinib. Merck’s commercial reach and BELLWAVE program enable broad combination testing.

Trajectory: Specifically, nemtabrutinib is the most direct pirtobrutinib challenger in non-covalent space. A successful Phase 3 readout could fragment the non-covalent BTKi class.

Key risk: However, the development gap behind pirtobrutinib is significant. Pirtobrutinib already has two FDA approvals and a positive EMA opinion before nemtabrutinib reaches Phase 3.

6. Nurix Therapeutics — NX-5948 / NX-2127 (Tier 2 — BTK degrader leader)

Primary route: BTK PROTAC degraders, with one dual-target degrader.

Key pipeline: NX-5948 (Bexobrutideg) — oral BTK PROTAC, Phase 1 in relapsed or refractory CLL and non-Hodgkin lymphoma. NX-2127 (Zelebrudomide) — dual BTK + IKZF1/IKZF3 degrader, Phase 1.

Differentiation: Specifically, BTK degraders bypass C481S, T474, L528W, and A428D resistance variants by removing the entire BTK protein rather than blocking its active site. The dual-degrader design (NX-2127) adds Aiolos depletion for combined BCR and immune-modulatory effects.

Trajectory: In addition, Phase 1 data in heavily pre-treated CLL show ORR signals at the lowest dose level. The architectural shift from inhibitor to degrader may define the next decade of BTK-directed therapy.

Key risk: However, PROTAC pharmacology (oral bioavailability, off-target degradation, immunological consequences) still needs Phase 3 validation. BeiGene’s BGB-16673 competes head-on with NX-5948 for the same patient population.

---

BD Deals & Strategic Moves

Key business development activity shaping the pirtobrutinib competitive landscape:

Date	Deal	Parties	Type	Significance
2019-08	Eli Lilly acquires Loxo Oncology	Lilly + Loxo	M&A ($8B)	Brought LOXO-305 (pirtobrutinib) into Lilly; defined the modern non-covalent BTKi franchise
2017-08	Loxo Oncology acquires Redx Pharma BTK assets	Loxo + Redx Pharma	Asset acquisition	Pirtobrutinib originated at Redx; Loxo paid $40M upfront for the BTKi platform
2023-01	Pirtobrutinib FDA accelerated approval (MCL)	Eli Lilly	Regulatory	First non-covalent BTKi approved; relapsed or refractory MCL after covalent BTKi
2023-12	Pirtobrutinib FDA accelerated approval (CLL/SLL)	Eli Lilly	Regulatory	Second indication; CLL/SLL after BTKi and BCL2i exposure
2025-02	EMA CHMP positive opinion for pirtobrutinib in R/R CLL	Eli Lilly	Regulatory	EU access for relapsed or refractory CLL after covalent BTKi failure
2024-2026	BRUIN CLL-322 active	Eli Lilly	Pivotal trial	EHA 2026 LB5001 — Phase 3 fixed-duration pirtobrutinib + venetoclax + rituximab vs venetoclax + rituximab
2024-2026	BRUIN CLL-321 active	Eli Lilly	Pivotal trial	Pirtobrutinib monotherapy vs IdelaR or BR in previously treated CLL
2024-2026	NX-5948 (Bexobrutideg) Phase 1 readouts	Nurix Therapeutics	Clinical milestone	BTK degrader Phase 1 shows activity in C481S-mutant disease; opens degrader-vs-non-covalent competition
2024-2026	BGB-16673 Phase 1 readouts	BeiGene / BeOne Medicines	Clinical milestone	Second BTK degrader with Phase 1 activity at lowest dose; intra-company hedge against zanubrutinib resistance
2024-2026	NX-2127 (Zelebrudomide) Phase 1 in CLL/DLBCL/FL	Nurix Therapeutics	Clinical milestone	Dual BTK + IKZF1/IKZF3 degrader; merges BTKi and CELMoD architectures

Strategic Pattern

Strategic pattern: Overall, the BD theme is architectural pivot. Lilly’s acquisition of Loxo defined non-covalent BTKi as a category in 2019; the 2023 FDA approvals established the salvage role; BRUIN CLL-322 now tests whether non-covalent BTKi can take a fixed-duration combination role. Meanwhile, the BTK degrader class (Nurix, BeiGene) compresses pirtobrutinib’s salvage advantage from the next direction. AbbVie, AstraZeneca, and BeiGene each maintain their covalent BTKi anchors; only BeiGene has hedged into the degrader class as well.

---

Unmet Needs & White Spaces

Notably, three white spaces meet all three criteria — sparse coverage, clear technical value, and a realistic entry path:

White Space	Current Coverage	Technical Value	Entry Path
Fixed-duration non-covalent BTKi regimens (time-limited combinations rather than continuous covalent BTKi)	Sparse — most covalent BTKi protocols run continuously; BRUIN CLL-322 is the first Phase 3 fixed-duration test of a non-covalent BTKi	High — addresses long-term toxicity, financial burden, and patient preference for time-limited therapy	BRUIN CLL-322 readout; community-oncology trials of pirtobrutinib + venetoclax with MRD-driven discontinuation
Post-non-covalent salvage (regimens after pirtobrutinib resistance via T474 or L528W variants)	Sparse — BTK degraders cover this need in Phase 1 but no Phase 3 data; CAR-T and bispecific options remain limited in CLL	High — 55% of pirtobrutinib progressors develop kinase-impaired BTK variants resistant to all BTKis	NX-5948, BGB-16673, and NX-2127 Phase 2 expansion; CD19 CAR-T in CLL; lisocabtagene maraleucel + ibrutinib data
Frontline non-covalent BTKi for older adults (treatment-naive CLL with cardiovascular comorbidities)	Sparse — frontline trials anchor on covalent BTKis; pirtobrutinib’s cleaner cardiac profile underexplored in untreated disease	High — older adults living with CLL face disproportionate atrial fibrillation and bleeding risk on ibrutinib	Phase 3 of pirtobrutinib monotherapy or pirtobrutinib + obinutuzumab in treatment-naive CLL with frailty stratification

---

Risks and Strategic Outlook for 2026 and Beyond

Key Risks

1. BTK degrader displacement: However, NX-5948, BGB-16673, and NX-2127 already show Phase 1 activity in patients who have cycled through both covalent and non-covalent BTKis. Specifically, the PROTAC architecture removes BTK rather than blocking it, which may render kinase-impaired variants irrelevant.
2. BRUIN CLL-322 readout dependency: Moreover, the EHA 2026 LB5001 readout reframes whether non-covalent BTKi anchors a fixed-duration combination. A miss compresses pirtobrutinib back to the salvage role.
3. Variant BTK resistance to non-covalent agents: Notably, BRUIN progressors develop T474 and L528W kinase-impaired variants in 55% of tested cases. The non-covalent advantage degrades in the same way that the C481S story did for ibrutinib, only faster.
4. Frontline migration to second-generation covalent agents: Furthermore, acalabrutinib and zanubrutinib have absorbed most of the frontline volume that ibrutinib once held. Pirtobrutinib needs a frontline trial to capture this segment, and BRUIN frontline arms are still early-stage.

Strategic Outlook

For strategic planning, the safest near-term bet around pirtobrutinib is fixed-duration combination expansion — pairing the non-covalent BTKi with venetoclax and an anti-CD20 antibody to extract a time-limited regimen that no covalent BTKi has fully claimed. However, the highest-upside, highest-risk bets are in frontline non-covalent BTKi for older adults with cardiovascular comorbidities and in combinations with BTK degraders that hit both wild-type and resistance-variant BTK simultaneously. White-space opportunities exist in MRD-driven discontinuation protocols and in patient-stratified frontline trials. The next two years of pirtobrutinib’s competitive position will depend less on the molecule’s potency and more on whether BRUIN CLL-322 establishes the fixed-duration role before BTK degraders mature into Phase 3 readouts.

If you want to generate similar competitive landscape reports for other targets, drugs, or companies, AI tools like Eureka LS can significantly reduce the time and effort required, while improving consistency and depth of analysis.